Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Redmond

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Oncoimmunology|June 7, 2018
The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironmentMohammad Farhad, Annah S Rolig, William L Redmond
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2003
Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APCWilliam L Redmond, Javier Hernandez, Linda A Sherman
Cancer Immunology Research|February 17, 2021
Enhancing the Generation of Eomes<sup>hi</sup> CD8<sup>+</sup> T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted ImmunotherapyDana A Emerson, Annah S Rolig, William L Redmond
European Journal of Immunology|August 13, 2009
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivoWilliam L Redmond, Michael J Gough, Andrew D Weinberg
Frontiers in Immunology|March 13, 2023
Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEAWilliam L Redmond, Melissa J Kasiewicz, Emmanuel T Akporiaye
Frontiers in Oncology|March 13, 2015
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the MetalStefanie N Linch, Michael J McNamara, William L Redmond
Critical Reviews in Immunology|June 23, 2009
The role of OX40-mediated co-stimulation in T-cell activation and survivalWilliam L Redmond, Carl E Ruby, Andrew D Weinberg
Cancer Immunology Research|April 30, 2014
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunityWilliam L Redmond, Stefanie N Linch, Melissa J Kasiewicz
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2020
Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8<sup>+</sup> T Cell DevelopmentMohammad Farhad Amani, Annah S Rolig, William L Redmond
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivoWilliam L Redmond, Boris C Marincek, Linda A Sherman
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Oncoimmunology|June 7, 2018
The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironmentMohammad Farhad, Annah S Rolig, William L Redmond
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2003
Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APCWilliam L Redmond, Javier Hernandez, Linda A Sherman
Cancer Immunology Research|February 17, 2021
Enhancing the Generation of Eomes<sup>hi</sup> CD8<sup>+</sup> T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted ImmunotherapyDana A Emerson, Annah S Rolig, William L Redmond
European Journal of Immunology|August 13, 2009
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivoWilliam L Redmond, Michael J Gough, Andrew D Weinberg
Frontiers in Immunology|March 13, 2023
Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEAWilliam L Redmond, Melissa J Kasiewicz, Emmanuel T Akporiaye
Frontiers in Oncology|March 13, 2015
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the MetalStefanie N Linch, Michael J McNamara, William L Redmond
Critical Reviews in Immunology|June 23, 2009
The role of OX40-mediated co-stimulation in T-cell activation and survivalWilliam L Redmond, Carl E Ruby, Andrew D Weinberg
Cancer Immunology Research|April 30, 2014
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunityWilliam L Redmond, Stefanie N Linch, Melissa J Kasiewicz
Journal of Immunology (Baltimore, Md. : 1950)|August 28, 2020
Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8<sup>+</sup> T Cell DevelopmentMohammad Farhad Amani, Annah S Rolig, William L Redmond
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivoWilliam L Redmond, Boris C Marincek, Linda A Sherman
Pageof 7